Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp brought in $6.5B of revenue over the twelve months to June 30, 2026, up 14.6% from a year earlier. Net income was $1B, a net margin of 15.4%. Operating cash flow minus capital spending left $1.3B of free cash flow in fiscal 2025. At June 30, 2026 it held $2.9B in cash against $598.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
What Edwards Lifesciences Corp does
Edwards Lifesciences designs and manufactures medical devices focused on structural heart disease and critical care monitoring. The company is best known for its transcatheter aortic valve replacement systems, surgical heart valves, and hemodynamic monitoring technologies sold to hospitals. Its shares trade on NYSE under the ticker EW.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.1B | $1.1B | $1.83 | $1.3B |
| 2024 | $5.4B | $4.2B | $6.97 | $289.9M |
| 2023 | $5B | $1.4B | $2.30 | $642.8M |
| 2022 | $4.5B | $1.5B | $2.44 | $973.6M |
| 2021 | $5.2B | $1.5B | $2.38 | $1.4B |
| 2020 | $4.4B | $823.4M | $1.30 | $647.3M |
Latest SEC filings
What Edwards Lifesciences Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 28, 2026
- August 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026
- July 23, 2026
- June 12, 2026
- June 12, 2026
- May 27, 2026
- May 8, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026
- May 4, 2026
Questions about EW
What does Edwards Lifesciences Corp do?
Edwards Lifesciences designs and manufactures medical devices focused on structural heart disease and critical care monitoring. The company is best known for its transcatheter aortic valve replacement systems, surgical heart valves, and hemodynamic monitoring technologies sold to hospitals. Its shares trade on NYSE under the ticker EW.
Is Edwards Lifesciences Corp profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $1B on revenue of $6.5B, a net margin of 15.4%.
How much revenue does Edwards Lifesciences Corp make?
Over the twelve months to June 30, 2026 Edwards Lifesciences Corp reported revenue of $6.5B. That is 14.6% more than a year earlier.
When did Edwards Lifesciences Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 14, 2026.
Similar companies
Follow EW
Get an email when Edwards Lifesciences Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow EW: get an email when it filesWhere the numbers come from
Financial figures are the values Edwards Lifesciences Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.